Comparative examination of Adalat and Cordaflex in anti-ischaemic therapy

Area of Science:

• Cardiology
• Pharmacology

Background:

• Ischaemic cardiomyopathy poses significant challenges in patient management.
• Nifedipine is a calcium channel blocker used for managing ischaemic heart conditions.

Purpose of the Study:

• To compare the anti-ischaemic efficacy of Cordaflex and Adalat in patients with ischaemic cardiomyopathy.
• To evaluate potential differences in blood pressure, heart rate, and side effects between the two nifedipine formulations.

Main Methods:

• A comparative study involving fifteen ischaemic cardiopathic patients.
• Patients received identical daily doses (30-80 mg) of Cordaflex and Adalat for one week each, alongside existing nitrate and beta-blocker therapy.
• Continuous 24-hour ECG monitoring was used to assess ischaemic periods.

Main Results:

• No significant differences in weekly nitroglycerin consumption or the duration/intensity of ischaemic periods were noted in 13 out of 15 patients.
• Observed changes in one patient during Cordaflex treatment and another during Adalat treatment were attributed to disease progression or spontaneous improvement.
• No differences were found in blood pressure, heart rate, or side effects between Cordaflex and Adalat.

Conclusions:

• Cordaflex and Adalat, both containing nifedipine, demonstrate identical anti-ischaemic effects in patients with ischaemic cardiomyopathy.
• The study suggests comparable efficacy and safety profiles for both nifedipine formulations in this patient population.